“In the third quarter, we made significant progress with commercial readiness plans in anticipation of FDA clearance for the 12-lead ECG synthesis software submission for arrhythmia assessment,” said Robert Eno, Chief Executive Officer, HeartBeam (BEAT). “We continue to engage in positive and productive discussions with the FDA and our anticipated timeline for this clearance by year end remains intact. Combined with the foundational FDA clearance received in December 2024, this clearance marks a major inflection point for the Company to initiate our commercial launch.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAT:
- HeartBeam (NASDAQ: BEAT) Recognized as a Top Global Innovator in Portable ECG Technology
- Heartbeam, Inc. (BEAT) Q3 Earnings Cheat Sheet
- HeartBeam (NASDAQ: BEAT) Initiated With Buy Rating and $4 Price Target by Roth Capital
- HeartBeam initiated with a Buy at Roth Capital
- HeartBeam (NASDAQ: BEAT) Schedules Third Quarter 2025 Conference Call for November 13